*The clinical significance of 100% inhibition has not been established.

BID=twice a day; BTK=Bruton's tyrosine kinase; PBMCs=peripheral blood mononuclear cells; QD=once a day.

2 Dosing Options1

  • Can be taken with or without food. Can be taken with a high-fat meal—BRUKINSA drug concentration (AUC) is not affected
  • Advise patients to swallow capsules whole with water—do not open, dissolve, or chew capsules
  • BRUKINSA must not be taken with grapefruit juice, grapefruit, and/or Seville oranges
  • If a dose of BRUKINSA is missed, it can be taken as soon as possible on the same day with a return to the normal schedule the following day

Treatment with BRUKINSA should continue until disease progression or unacceptable toxicity.

Dose Modification for ≥Grade 3 ARs1

ARs that require dose modification

  • Grade 3 or higher non-hematological toxicities
  • Grade 3 febrile neutropenia
  • Grade 3 thrombocytopenia with significant bleeding
  • Grade 4 neutropenia (lasting more than 10 consecutive days)
  • Grade 4 thrombocytopenia (lasting more than 10 consecutive days)

Recommended Dose Modification by Occurrence for ≥Grade 3 ARs

AR=adverse reaction; AUC=area under the plasma drug concentration over time curve; BID=twice a day; BTK=Bruton's tyrosine kinase; CI=confidence interval; CR=complete response; ECOG=Eastern Cooperative Oncology Group; IRC=independent review committee; MR=minor response; PD=progressive disease; PPI=proton pump inhibitor; QD=once a day; R/R=relapsed/refractory; TN=treatment-naïve; VGPR=very good partial response; WM=Waldenström’s macroglobulinemia.

BRUKINSA Ordering Information

BRUKINSA is supplied through Sentrex Health Solutions
For product ordering information, please call 1-833-234-4366 
or email info@mybeigene.ca

 Patient Support Dedicated to Helping Patients

A personalized and comprehensive support program designed to help guide and assist patients, caregivers, and practices.

Complete commitment to your patients

The program is staffed with nurses who have prior experience working with oncology patients

Practices and their patients get a dedicated Oncology Nurse Advocate assigned to them

We seek to offer comprehensive patient support, including connecting patients to helpful resources that can address their personal needs

The myBeiGene program is designed to provide appropriate information and assistance to patients, including:

Reimbursement/payment support

  • Insurance verification support
  • Bridge, co-pay, and free product for certain eligible patients

Education and support

  • Helps provide information about their disease and treatment with BRUKINSA
  • Patient and caregiver follow-up support
  • Dedicated Oncology Nurse Advocates for practices, patients, and caregivers

Connections to third-party advocacy organizations

  • Assists patients and caregivers with practical help through connections to advocacy groups and local/national free resources such as:
    • Counseling services
    • Support group information

Enroll in myBeiGene

Call myBeiGene


Fax Enrollment Form to 1-833-567-0696



BeiGene provides you with samples of BRUKINSA (zanubrutinib) for your patients

Receive a sample in 2 easy steps


Click “Request Sample” below or request a sample form from your Regional Manager.

Complete the form and submit.
Receive the sample(s) in approximately two business days, shipped directly to your office.
Each sample request for BRUKINSA is fulfilled with up to two 120-count bottle(s), each bottle allocated for one patient.
Your BeiGene Regional Manager will provide you with patient materials to accompany the sample(s).
Upon enrollment into the myBeiGene Patient Support Program, a BRUKINSA Patient Starter Kit will be provided.
These are prescription drug samples provided in accordance with Food and Drug Regulations.
It is unlawful to sell, trade, barter, return for credit, utilize to seek reimbursement or bill patients for samples.